Premium
Patient‐specific mutation databases for oral cancer
Author(s) -
Partridge M.,
Emilion G.,
Falworth M.,
A'Hern R.,
Phillips E.,
Pateromichelakis S.,
Langdon J.
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990621)84:3<284::aid-ijc15>3.0.co;2-y
Subject(s) - loss of heterozygosity , cancer , allele , mutation , biology , database , stage (stratigraphy) , head and neck cancer , oncology , gene , bioinformatics , medicine , genetics , paleontology , computer science
Development of databases, summarising the genetic events associated with oral squamous cell carcinoma (SCC), should increase our understanding of the molecular basis of these lesions. Additionally, databases will help establish whether different cancer subtypes show different growth characteristics, because the multistage carcinogenic process is different in the various tumour subtypes. This new knowledge may also provide new prognostic information, as these aberrations represent fundamental biological characteristics of each tumour. To assess the value of incorporating the results from loss of heterozygosity (LOH) analysis into patient‐specific mutation databases, we have carried out microsatellite analysis with 52 polymorphic markers at 13 key chromosomal regions implicated in the pathogenesis of head and neck cancers. Altered expression of the Rb , p53 and DCC tumour suppressor genes has also been studied by immunohistology. Our results shed light on the different pathways that lead to cancer and reveal that a variety of different patterns of allelic imbalance (AI) were detected at all TNM stages, reflecting the different clinical behaviour that tumours classified as being of the same TNM stage may exhibit. Summarising the level of genetic damage as a fractional allelic loss (FAL) score and the presence of AI at 3p22–26, 3p14.3–12.1 and 9p21 was found to be a better predictor of outcome than the TNM system. This finding suggests that molecular data can be incorporated into conventional staging systems to provide more accurate prognostic information for this group of patients. Int. J. Cancer (Pred. Oncol.) 84:284–292, 1999. © 1999 Wiley‐Liss, Inc.